Bolt Biotherapeutics, Inc. Payments for Restructuring
Bolt Biotherapeutics, Inc. (BOLT) reported Payments for Restructuring of $700.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2026-03-12
- Bolt Biotherapeutics, Inc. payments for restructuring for the quarter ending 2025-12-31 was $15.00K, a 97.41% decline year-over-year.
- Bolt Biotherapeutics, Inc. payments for restructuring for the quarter ending 2025-09-30 was $37.00K, a 97.28% decline year-over-year.
- Bolt Biotherapeutics, Inc. payments for restructuring for the quarter ending 2025-06-30 was $241.00K.
- Bolt Biotherapeutics, Inc. payments for restructuring for the quarter ending 2025-03-31 was $407.00K.
- Bolt Biotherapeutics, Inc. payments for restructuring for fiscal 2025 was $700.00K, a 63.16% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. payments for restructuring for fiscal 2024 was $1.90M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2025-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $52.00K derived: sum of 2 quarters · filed 2026-03-12 | $293.00K derived: sum of 3 quarters · filed 2026-03-12 | $700.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $37.00K 10-Q · filed 2025-11-12 | $278.00K derived: sum of 2 quarters · filed 2025-11-12 | $685.00K 10-Q · filed 2025-11-12 | $1.26M derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $241.00K 10-Q · filed 2025-08-14 | $648.00K 10-Q · filed 2025-08-14 | $1.23M derived: sum of 3 quarters · filed 2025-08-14 | $2.59M derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $407.00K 10-Q · filed 2025-05-12 | $986.00K derived: sum of 2 quarters · filed 2025-05-12 | $2.35M derived: sum of 3 quarters · filed 2025-05-12 | $2.35M derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | $579.00K derived: 10-K 6 month − 10-Q 3 month · filed 2025-03-24 | $1.94M 10-K · filed 2025-03-24 | $1.94M derived: sum of 3 quarters · filed 2025-03-24 | $1.90M 10-K · filed 2025-03-24 |
| 2024-09-30 | $1.36M 10-Q · filed 2024-11-12 | $1.36M derived: sum of 2 quarters · filed 2024-11-12 | $1.40M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | -$40.00K derived: 10-K 12 month − 3 quarters · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |